Survanta 25 mg (Beractant SUSPENSION) 25 MG

Survanta 25 mg is a beractant suspension used for respiratory support in premature infants. This intratracheal medication helps improve lung function and reduce respiratory distress.

Strength

25 MG

Pack Size

4ML/8ML

Manufacturer / TM Owner

ABBVIE CORPORATION

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Survanta 25 mg is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed, leading to difficulty breathing. Survanta works by replacing natural surfactants in the lungs, which helps the lungs expand more easily. It is administered intratracheally, directly into the airways, to provide immediate support.

Side Effects

Common effects of Survanta 25 mg may include improved breathing and reduced need for ventilator support in premature infants. The medication helps the lungs function more effectively by reducing surface tension, making it easier for the infant to breathe. Some infants may experience mild side effects, but these are generally managed by healthcare providers.

Precautions & Warnings

Survanta 25 mg should be used under the supervision of a healthcare professional. It is important to follow the prescribed dosage and administration guidelines to ensure safety and effectiveness. Infants with certain medical conditions or allergies may require special monitoring. Always consult a healthcare provider before use.

Avoid Interactions

Survanta 25 mg may interact with other medications or treatments. It is important to inform your healthcare provider about any other medications the infant is taking. Certain medications or substances may affect the effectiveness or safety of Survanta. Always follow the advice of a healthcare professional regarding potential interactions.

Frequently Asked Questions

Survanta 25 mg is used to treat respiratory distress syndrome in premature infants by replacing natural surfactants in the lungs.

Survanta 25 mg is administered intratracheally, directly into the airways, to provide immediate respiratory support.

Common effects include improved breathing and reduced need for ventilator support in premature infants.

Survanta 25 mg should be used under the supervision of a healthcare professional, and infants with certain conditions may require special monitoring.

Survanta 25 mg may interact with other medications, so it is important to inform your healthcare provider about any other treatments the infant is receiving.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.